Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
Mascarenhas L, DuBois SG, Albert CM, Bielack S, Orbach D, Federman N, Geoerger B, Nagasubramanian R, Zhang Y, Chisholm J, Gallego Melcon S, Goto H, Morgenstern DA, Owens C, Pappo AS, Perreault S, Schulte JH, Shukla N, Zwaan CM, Neu N, Bernard-Gauthier V, De La Cuesta E, van Tilburg CM, Laetsch TW.
Mascarenhas L, et al. Among authors: zhang y.
J Clin Oncol. 2025 Jan 27:JCO2400848. doi: 10.1200/JCO.24.00848. Online ahead of print.
J Clin Oncol. 2025.
PMID: 39869835